A non-interventional post-marketing surveillance study carried out between January 2012 and October 2013 on 1,537 patients in 15 centres showed that Dotarem® (Guerbet, Roissy, France) is an effective contrast agent for the identification of invasive ductal carcinomas. An MR mammography with the diagnosis of invasive ductal carcinoma was confirmed in 93.5% of all cases by means of a subsequent cytological examination. Overall, a diagnosis was able to be made in 99.2% of the cases. Adverse reactions occurred in 5 patients (0.3%). In 4 out of 5 of the patients the adverse events were not serious and in one patient the adverse events were serious.
